NCT03049774View on ClinicalTrials.gov

A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor

UnknownOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Chemotherapy-induced Thrombocytopenia
Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Angde Biotech Pharmaceutical Co., Ltd.

INDUSTRY

NCT03049774 - A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor | Biotech Hunter | Biotech Hunter